KLRG1, Another Opportunity for a Breakthrough in MTCL.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38568191.
- Also identified by DOI 10.1158/1078-0432.CCR-24-0374.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Outcomes in mature T-cell lymphomas remain poor, with previous attempts at developing mAbs compromised by limited efficacy and significant immunocompromise. Anti-killer cell lectin-like receptor G1 mAbs may have greater selectivity and specificity for malignant T cells and avoid the toxicity concerns with previous agents. See related article by Assatova et al., p. 2514.
Medical subject headings
- Lectins, C-Type